Methylphenidate-induced dyskinesia, an underrecognized adverse effect In ADHD treatment
DOI:
https://doi.org/10.25753/BirthGrowthMJ.v34.i3.26248Keywords:
attention deficit hyperactivity disorder, dyskinesia, methylphenidate, PediatricsAbstract
Attention deficit hyperactivity disorder (ADHD) is one of the leading mental and behavioral disorders in childhood and adolescence and remains a clinical challenge for healthcare professionals. Methylphenidate (MPH) is the first-line pharmacological treatment option for children over six years of age, but it is not without side effects. While the most common are mild and reversible upon therapy discontinuation, less recognized complications may occur, such as MPH-induced dyskinesia. Dyskinesia may present acutely, with the sudden onset of involuntary movements shortly after MPH administration (acute dyskinesia) or tardively, developing gradually after weeks of treatment (tardive dyskinesia). The cause of this drug-induced effect remains unclear. Herein is reported the first case in the literature of a patient with ADHD who developed symptoms of acute and tardive dyskinesia while receiving MPH. This case highlights the importance of awareness and early recognition of this rare but potentially stigmatizing adverse effect.
Downloads
References
Austerman J. ADHD and behavioral disorders: Assessment, management, and an update from DSM-5. Cleve Clin J Med. 2015 Nov;82(11 Suppl 1):S2-7. doi: https://doi.org/10.3949/ccjm.82.s1.01.
Wolraich ML, Jr JFH, Allan C, Chan E, Davison D, Earls M, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;144(4):e20192528. doi: https://doi.org/10.1542/peds.2019-2528.
Cortese S, Adamo N, Giovane CD, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2018;5(9):727-38.
Faraone SV. The Pharmacology of Amphetamine and Methylphenidate: Relevance to the Neurobiology of Attention-Deficit/Hyperactivity Disorder and Other Psychiatric Comorbidities. Neurosci Biobehav Rev. 2018;87:255-270. doi: https://doi.org/10.1016/j.neubiorev.2018.02.001.
Leache L, Arrizibita O, Gutiérrez-Valencia M, Saiz LC, Erviti J, Librero Jn. Incidence of Attention Deficit Hyperactivity Disorder (ADHD) Diagnoses in Navarre (Spain) from 2003 to 2019. Int J Environ Res Public Health. 2021;18(17):9208. doi: https://doi.org/10.3390/ijerph18179208.
Espadas M, Insa I, Chamorro M, Alda-Díez JA. Efectos secundarios del metilfenidato en población infantil y juvenil. Rev Neurol. 2018;66(5):157-162.
Shellenberg TP, Stoops WW, Lile JA, Rush CR. An update on the clinical pharmacology of methylphenidate: therapeutic efficacy, abuse potential and future considerations. Expert Rev Clin Pharmacol. 2020;13(8):825-833. doi: https://doi.org/10.1080/17512433.2020.1796636 .
Verghese C, Abdijadid S. Methylphenidate: StatPearls Publishing, Treasure Island (FL); 2021 May 4, 2021. www.ncbi.nlm.nih.gov/books/NBK482451/.
Storebø O, Ramstad E, Krogh H, Nilausen T, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) (Review). Cochrane Database of Systematic Reviews. 2015(11).
Lee M, Wang L. Methylphenidate-induced Orofacial Dyskinesia: Report of Two School-age Boys in Taiwan. Hong Kong Journal of Paediatrics (new series). 2017;22(2):107-9.
Senecky Y, Lobel D, Diamond GW, Weitz R, Inbar D. Isolated orofacial dyskinesia: A methylphenidate-induced movement disorder. Pediatric Neurology. 2002;27(3):224-6.
Gokcen C, Karadag M, Aksoy I. Methylphenidate Induced Lip and Tongue Biting. Clinical Psychopharmacology and Neuroscience. 2018;16(2):218-20.
Millichap JG. Risk of Tics with Psychostimulants for ADHD. Pediatric Neurology Briefs. 2015;29(12):1.
Keresztény Á, Ferenczi-Dallos G, Velő S, Gádoros J, Balázs J. Dyskinesia in Treatment-Naive and Stimulant-Treated Children With ADHD. J Atten Disord. 2020;24(7):981-989. doi: https://doi.org/10.1177/1087054716679262.
Arslan EA, Arslan E, Kılınç A, Göksu Ö. Effect of biperiden treatment in acute orofacial and extremity dyskinesia with methylphenidate therapy. Pediatr Emerg Care. 2018;34(11):e217-e218. doi: https://doi.org/10.1097/PEC.0000000000001102.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Teresa Pinheiro, Carla Maia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in the Birth and Growth Medical Journal are Open Access and meet the requirements of funding agencies and academic institutions. Third-party use of published content is permitted under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) license. It is the responsibility of authors to obtain permission for reproducing figures, tables, or other materials from previously published works.
Authors must submit a Conflict of Interest statement and an Authorship Form together with their manuscript. A confirmation email will be sent to the corresponding author upon receipt of the submission. Authors are also permitted to deposit their articles in institutional or personal repositories, provided that the original publication in the Birth and Growth Medical Journal is clearly indicated and the terms of the Creative Commons license are respected.
